forum

DRREDDY Share Price Discussion

Dr. Reddy's Laboratories Ltd.
Sector: Pharmaceuticals and health care
... Read more
DRREDDY Share Price *
2,534.95 +31.95 (1.28%)
* (quote may be delayed)
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY Share Price - Technicals

    keyboard_arrow_down
    DRREDDY - 52 Week High₹2,964
    DRREDDY - 52 Week Low₹1,872.95

DRREDDY Discussion Forum

These 7 'lucky' stocks saw EPS upgrades in last 3 of 4 quarters; time to buy?
Investors should pick those stocks which are displaying signs of consistent growth.
Moneycontrol
Like
reply
Reply
share
Share

Dr reddy trading at 2546, it will go more up from here
Like
reply
Reply (3)
share
Share
Latest replies

2560 now rocks even in this type of market almost 17bpojnt jntrday
An evening walk down D-St: Sensex, Nifty fall for 2nd day in a row; Yes Bank, Tata Motors crash
Broader Midcap and Smallcap indices underperformed Sensex, falling 1.32 percent and 1.43 percent, respectively.
Moneycontrol
Like
reply
Reply
share
Share
These 12 Nifty stocks trading at discount to 5-yr avg P/E; time to buy?
The golden rule of investment is to pour money in stocks that are trading at attractive levels compared to their intrinsic value, thus allowing investors to create wealth over a period of time
Moneycontrol
Like
reply
Reply
share
Share
Dr Reddy's slips 2% after USFDA issues 8 observations for Andhra facility
The company said it will address them comprehensively within the stipulated timeline.
Moneycontrol
Like
reply
Reply
share
Share
Stocks in the news: SPARC, SpiceJet, Alembic Pharma, Dr Reddys Labs, United Spirits, Deepak Nitrite
Alembic Pharma | Dr Reddy's Labs | United Spirits | HDIL | Deepak Nitrite | IOL Chemicals and Freshtrop Fruits are stocks which are in the news today.
Moneycontrol
Like
reply
Reply
share
Share
Dr Reddy’s gains on launch of Vigabatrin powder
The company launched Vigabatrin powder in 500 mg per packet, a therapeutic equivalent generic version of Sabril (vigabatrin) powder, approved by the US Food and Drug Administration (USFDA).
Moneycontrol
Like
reply
Reply
share
Share

Dr Reddy - Dr Reddy has received 8 observations for its Duvada facility. It is the same plant for which the company had earlier got warning letter but got cleared in Feb'19. The current observations are after the pre-approval inspection for the new line added in the same plant. ...
Read more...
Like
reply
Reply
share
Share

CITI on DRL 483s at Duvvada– Nature Unknown, Likely Sentiment Dampener
Observations routine post FDA inspections, & most not meaningfully disruptive
Fact that this plant has been inspected successfully twice within last yr provides some comfort
Expect overhang on stk
Like
reply
Reply
share
Share

Sell DRREDDY CASH BLW 2530 SL 2545
Like
reply
Reply
share
Share

Buy DRREDDY ABV 2540 for 2550 2560 2570
Sl 15 points
Like
reply
Reply (1)
share
Share
Latest replies

First trgt achieved
High made 2558.85
4712 profit👍👍👍👍

Drreddy fut sell 2563
Sl-2574
Trg-2560/2555/2550 🔥🔥✌️✌️
Like
reply
Reply (1)
share
Share
Latest replies
Rajmudra Stock @rajmudra
Aug 19 4:12 PM

Second target achieve small invester book profit
Top buy and sell ideas by Sudarshan Sukhani, Mitessh Thakkar, Prakash Gaba for short term
Prakash Gaba of prakashgaba.com suggets buying Bajaj Auto Pharma with target at Rs 2810 and stop loss at Rs 2717.
Moneycontrol
Like
reply
Reply
share
Share
Dr Reddy’s falls nearly 2% after co clarifies on NuvaRing-USFDA issue; Citi cuts target by 6.5%
The USFDA sends the applicant a CRL if the agency determines that it will not approve the application, or ANDA, in its present form for one or more reason
moneycontrol.com
Like
reply
Reply
share
Share
Chart Check: Where are Sun Pharma, Glenmark headed after a 5-10% fall in two days?
Sun Pharma which reported healthy numbers in June quarter failed to hold onto gains and lost momentum largely due to growing concerns in US and management rejig
moneycontrol.com
1
reply
Reply
share
Share
Chart Check: Where is Sun Pharma, Glenmark headed after 5-10% fall in two days?
Sun Pharma which reported healthy numbers in June quarter failed to hold onto gains and lost momentum largely due to growing concerns in US and management rejig
moneycontrol.com
Like
reply
Reply
share
Share
Chart Check: Where is Sun Pharma, Glenmark headed after Wednesday’s 4-8% fall?
Sun Pharma which reported healthy numbers in June quarter failed to hold onto gains and lost momentum largely due to growing concerns in US and management rejig
www.moneycontrol.com
Like
reply
Reply
share
Share
An evening walk down Dalal Street: Delayed US tariffs lift market sentiments
The breadth of the market also improved as 1,319 stocks logged gains against 1,156 that suffered losses. As many as 140 stocks remained unchanged
moneycontrol.com
Like
reply
Reply
share
Share
Dr Reddy’s dips 8% after receiving Complete Response Letter from USFDA; Citi cuts target
Global brokerage Citi slashed price target to Rs 2,375 from Rs 2,540 per share, citing likely more delay in female contraceptive drug launch after fresh Complete Response Letter from US FDA.
moneycontrol.com
Like
reply
Reply
share
Share
link

invst.ly

Buy DR Reddy SEP Fut above 2610 for a target of 2650.
Stoploss : 2570
Reason: Inverse Head and Shoulder (Look at the chart below)
Like
reply
Reply (1)
share
Share
Latest replies

No Clear Confirmation. Please exit the trade

BUY DRM REDDYS LABS ABOVE 2595,,,SL URS,,,TGT OPEN
Like
reply
Reply
share
Share
Mitsubishi UFJ Financial Group raises stake in Dr Reddy’s to 8.41%
Before the acquisition, MUFG held 0.05 percent stake in Dr Reddy’s.
moneycontrol.com
Like
reply
Reply
share
Share
MAGIC OF INTRA (MOI) in DRREDDY
buy nifty fut 10933 sl 10880 tgt 10990/11110

First Target hit
Like
reply
Reply
share
Share

buy nifty fut 10933 sl 10880 tgt 10990/11110
Like
reply
Reply
share
Share

buy dr reddy fut 2566 sl 2556 tgt 2614/2677/2810
Like
reply
Reply
share
Share

Buy drreddyy 2600 ce @56 tgt 66 sl not required
@61.50
Like
reply
Reply
share
Share
Equity millionaire in DRREDDY
BUY DRREDDY AT 2508-10 SL 2495 T 2530,2555

First target done 🔥🔥🔥🔥
1
reply
Reply
share
Share
‘Nifty could see a pullback but that could results in a ‘dead cat bounce’
The markets can see some pullback from the range of 10,800-10,850. Earlier support of 200-DMA can interchange its role as a resistance going forward for the Nifty.
moneycontrol.com
Like
reply
Reply
share
Share

BUY DRREDDY AT 2508-10
SL 2495
T 2530,2555
Like
reply
Reply
share
Share
70% of BSE500 universe trading below 200-DMA; what should you do?
In technical trading, moving averages such as the 50-DMA, 200-DMA act as both support and resistance levels for the stock
moneycontrol.com
Like
reply
Reply
share
Share

DRREDDY - chart - 298388
Drreddy
Like
reply
Reply
share
Share
India Inc performance: Hits and misses of June quarter earnings
Dr Reddy’s Labs, ICICI Bank, State Bank of India and HDFC reported profit while on the other hand, Bharti Airtel disappointed the Street.
www.moneycontrol.com
Like
reply
Reply
share
Share
Sun Pharma’s Dilip Shanghvi took home Re 1 as salary in FY19, a 99% cut
Shanghvi’s salary was around Rs 3 crore in FY18
moneycontrol.com
Like
reply
Reply
share
Share
PROFIT MACHINE in DRREDDY
Sell DRREDDY CASH 2556 SL 2576

DRREDDY CASH 2501🏃🏃🏃🏃
Like
reply
Reply
share
Share
PROFIT MACHINE in DRREDDY
Sell DRREDDY CASH 2556 SL 2576

DRREDDY CASH 2514
Like
reply
Reply
share
Share
PROFIT MACHINE in DRREDDY
Sell DRREDDY CASH 2556 SL 2576

DRREDDY CASH 2518🏃🏃🏃🏃
Like
reply
Reply
share
Share
PROFIT MACHINE in DRREDDY
Sell DRREDDY CASH 2556 SL 2576

2540 🏃🏃🏃
Like
reply
Reply
share
Share
PROFIT MACHINE in DRREDDY
Sell DRREDDY CASH 2556 SL 2576

2551🏃🏃
Like
reply
Reply
share
Share

Sell DRREDDY CASH 2556 SL 2576
Like
reply
Reply
share
Share

DRREDDY - chart - 293468
FREE OPTION CALL GIVEN TODAY AT MY TELEGRAM CHANNEL
Like
reply
Reply
share
Share
Buy Dr. Reddy’s Labs; target of Rs 3360: HDFC Securities
HDFC Securities is bullish on Dr. Reddy’s Labs has recommended buy rating on the stock with a target price of Rs 3360 in its research report dated July 30, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Accumulate Dr. Reddy’s Laboratories; target of Rs 2997: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Dr. Reddy’s Laboratories with a target price of Rs 2997 in its research report dated July 29, 2019.
moneycontrol.com
Like
reply
Reply
share
Share

Sell DRREDDY at the beginning of the Market
Avoid if it opens huge Gap Down
Strict Stop Loss - 2590.75
1st target is always realistic 1% of your Entry Price(trail ur Sl)
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please consult with your financial ...
Read more...
Like
reply
Reply
share
Share
safe portfolio in DRREDDY
Swing trade levels for 30-7-19 ◆buy above 2665 for target 2677.75-2690-2705. sl-2652. ●sell belo...

Below 2652 all targets hit
Like
reply
Reply
share
Share
Ggg in DRREDDY
2595 exit from Dr reddy position, no wait for sl👈

V exited Drreddy in 10 penny loss, now bc 30 penny down below 2550😢😒😭
Like
reply
Reply
share
Share
Ggg in DRREDDY
High risk short Dr Reddy fut @2582-85, sl 2610, tgt below 2500

2595 exit from Dr reddy position, no wait for sl👈
Like
reply
Reply
share
Share
Warning letter woes: Dr Reddy’s expects FDA inspection of Andhra Pradesh plant by year end
"On the regulatory front, the API plant at Miryalaguda was given an Establishment Inspection Report (EIR) in 2017 resolving the earlier warning letter. We also received EIR for the injectable site at the Duvvada and we are awaiting for CTO VI site at Srikakulam.
moneycontrol.com
Like
reply
Reply
share
Share
Ggg in DRREDDY
High risk short Dr Reddy fut @2582-85, sl 2610, tgt below 2500

Dr reddy once below 2550 on nse will brake peace by closing below 2500 today eod😥
Like
reply
Reply
share
Share
MAGIC OF INTRA (MOI) in DRREDDY
buy dr reddy lab above 2640 sl 2625 tgt 2659/2680/2715/2760

not activated
Like
reply
Reply
share
Share

High risk short Dr Reddy fut @2582-85, sl 2610, tgt below 2500
Like
reply
Reply
share
Share
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    2-Aug-19Nirmal BangBuy3,281
    31-Jul-19HDFC SecuritiesBuy3,360
    30-Jul-19Prabhudas LilladherAccumulate2,997
    30-Jul-19ICICIdirect.comHold2,840
    14-Jun-19EdelweissBuy3,400
    View all DRREDDY - Share Targets - Broker Reports
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 2125002526.924912503
    Aug 202524.752564.452515.52554.6
    Aug 1925402568.9524952509.1
    Aug 162529252924652492.55
    Aug 142525.052537.82351.22511.95
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹2,565.48
    30 Day Moving Average₹2,588.21
    50 Day Moving Average₹2,584.61
    100 Day Moving Average₹2,677.67
    200 Day Moving Average₹2,647.46
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Today 3:28 PM
    These 7 'lucky' stocks saw EPS upgrades in last 3 of 4 quarters; time to buy?
    Moneycontrol
    NewsBot
    Yesterday 10:38 PM
    An evening walk down D-St: Sensex, Nifty fall for 2nd day in a row; Yes Bank, Tata Motors crash
    Moneycontrol
    NewsBot
    Yesterday 3:33 PM
    These 12 Nifty stocks trading at discount to 5-yr avg P/E; time to buy?
    Moneycontrol
    NewsBot
    Yesterday 3:29 PM
    Dr Reddy's slips 2% after USFDA issues 8 observations for Andhra facility
    Moneycontrol
    NewsBot
    Yesterday 3:29 PM
    Stocks in the news: SPARC, SpiceJet, Alembic Pharma, Dr Reddys Labs, United Spirits, Deepak Nitrite
    Moneycontrol
    NewsBot
    Yesterday 3:28 PM
    Dr Reddy’s gains on launch of Vigabatrin powder
    Moneycontrol
    NewsBot
    Aug 19 1:58 PM
    Top buy and sell ideas by Sudarshan Sukhani, Mitessh Thakkar, Prakash Gaba for short term
    Moneycontrol
    NewsBot
    Aug 16 7:18 PM
    Dr Reddy’s falls nearly 2% after co clarifies on NuvaRing-USFDA issue; Citi cuts target by 6.5%
    moneycontrol.com
    NewsBot
    Aug 16 4:43 PM
    Chart Check: Where are Sun Pharma, Glenmark headed after a 5-10% fall in two days?
    moneycontrol.com
    NewsBot
    Aug 16 4:13 PM
    Chart Check: Where is Sun Pharma, Glenmark headed after 5-10% fall in two days?
    moneycontrol.com
  • DRREDDY - Related Communities

    keyboard_arrow_down
    Help fellow traders de-stress by shar...
    Share and discuss strategies for tax ...
    Want to know more about an upcoming I...
    MCX:MENTHAOIL
    MCX:CPO
    Purpose: Pool and discuss ideas & sug...
    Sector: Index
    Sector: Finance
    Share LINKS, VIDEOS, SITES, BOOKS, JO...
    Share insightful expert analysis and ...
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.